AMGN · NASDAQ
Amgen
Biotechnology with a monthly-dosed peptide-antibody obesity candidate (MariTide) in Phase 2.
HQ Thousand Oaks, CA, USA
Market cap Large
Focus Bispecific peptide antibody conjugates
Investor relations ↗Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research
Overview
Pipeline programs
3Active trials
1Upcoming catalysts
1Indications
2ObesityCardiometabolic
AI research summary
Generated on demand from verified profile data.
The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.
Pipeline
Clinical trials
Upcoming catalysts
- Apr 10, 2026Source ↗
MariTide Phase 2 obesity readout window
Readout · Window
Timeline
Merged approvals, trial milestones, and catalysts. Newest first.
Jun 01, 2026 · Trial Milestone
Phase 2 · MariTide obesity Phase 2 — primary completion (active, not recruiting)
ClinicalTrials.gov ↗Apr 10, 2026 · Corporate
MariTide Phase 2 obesity readout window
Source ↗Nov 26, 2024 · Trial Milestone
Amgen reports 52-week Phase 2 MariTide (maridebart cafraglutide) obesity data.
Amgen IR ↗
Verified sources
- [1]Amgen IR — Amgen Inc.retrieved 2026-07-15
- [2]SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
- [3]ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15
SEC filings search: EDGAR ↗